Overview

Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, double-blind, randomized, placebo-controlled, Phase Ib/IIa clinical study to assess the administration of ApTOLL together with endovascular therapy in acute ischemic stroke patients who are candidates to receive reperfusion therapies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
aptaTargets S.L.
Collaborators:
Anagram
Science and Innovation Spanish Ministry